journal article·2018-12-26

Ferrous-Supply-Regeneration Nanoengineering for Cancer-Cell-Specific Ferroptosis in Combination with Imaging-Guided Photodynamic Therapy

Tao Liu, Wenlong Liu, Mingkang Zhang, Wuyang Yu, Fan Gao, Chuxin Li, Shi-Bo Wang, Jun Feng, Xian-Zheng Zhang

ACS Nano· Volume 12· Issue 12
Publisher page

Abstract

Non-apoptotic ferroptosis is of clinical importance because it offers a solution to the inevitable biocarriers of traditional apoptotic therapeutic means. Inspired by industrial electro-Fenton technology featured with electrochemical iron cycling, we construct ferrous-supply-regeneration nanoengineering to intervene tumorous iron metabolism for enhanced ferroptosis. Fe3+ ion and naturally derived tannic acid (TA) spontaneously form a network-like corona onto sorafenib (SRF) nanocores. The formed SRF@FeIIITA nanoparticles can respond to a lysosomal acid environment with corona dissociation, permitting SRF release to inhibit GPX4 enzyme for ferroptosis initiation. TA is arranged to chemically reduce the liberated and the ferroptosis-generated Fe3+ to Fe2+, offering iron redox cycling to, thus, effectively produce lipid peroxide required in ferroptosis. Sustained Fe2+ supply leads to long-term cytotoxicity, which is identified to be specific to H2O2-overloaded cancer cells but minimal in normal cells. SRF@FeIIITA-mediated cell death proves to follow the ferroptosis pathway and strongly inhibits tumor proliferation. Moreover, SRF@FeIIITA provides a powerful platform capable of versatile integration between apoptosis and non-apoptosis means. Typically, photosensitizer-adsorbed SRF@FeIIITA demonstrates rapid tumor imaging owing to the acid-responsive fluorescence recovery. Together with ferroptosis, imaging-guided photodynamic therapy induces complete tumor elimination. This study offers ideas about how to advance anticancer ferroptosis through rational material design.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Nanoplatforms for cancer theranostics · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, PR China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1016/S0092-8674(02)00625-610.1016/S0092-8674(02)00625-6 ↗
2. 10.1038/sj.onc.120960810.1038/sj.onc.1209608 ↗
3. 10.1038/3503771010.1038/35037710 ↗
4. 10.1002/adma.20160415710.1002/adma.201604157 ↗
5. 10.1002/adfm.20170682710.1002/adfm.201706827 ↗
6. 10.1021/acs.chemmater.7b0324110.1021/acs.chemmater.7b03241 ↗
7. 10.1038/nrc288910.1038/nrc2889 ↗
8. 10.1038/leu.2014.5610.1038/leu.2014.56 ↗
9. 10.1038/nrc156010.1038/nrc1560 ↗
10. 10.1038/nrc70610.1038/nrc706 ↗
11. 10.1038/onc.2011.53910.1038/onc.2011.539 ↗
12. 10.1016/j.jtbi.2015.10.01910.1016/j.jtbi.2015.10.019 ↗
13. Misale S. · Nature · 2012 · 486 · 53210.1038/nature11156 ↗
14. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
15. 10.1038/nature1434410.1038/nature14344 ↗
16. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
17. 10.1038/nchembio.223810.1038/nchembio.2238 ↗
18. 10.1016/j.tcb.2015.10.01410.1016/j.tcb.2015.10.014 ↗
19. 10.1021/acs.nanolett.6b0406010.1021/acs.nanolett.6b04060 ↗
20. 10.1016/j.apcatb.2016.01.01510.1016/j.apcatb.2016.01.015 ↗
21. 10.1038/nchembio.141610.1038/nchembio.1416 ↗
22. 10.1038/nchembio.107110.1038/nchembio.1071 ↗
23. 10.1016/S0092-8674(04)00343-510.1016/S0092-8674(04)00343-5 ↗
24. 10.1021/cr900136g10.1021/cr900136g ↗
25. 10.1007/s12013-009-9043-x10.1007/s12013-009-9043-x ↗
26. 10.1126/science.123726510.1126/science.1237265 ↗
27. 10.1038/nrd280310.1038/nrd2803 ↗
28. Szatrowski T. P. · Cancer Res. · 1991 · 51 · 794
29. 10.1016/j.canlet.2006.10.02910.1016/j.canlet.2006.10.029 ↗
30. 10.1016/0891-5849(94)00198-S10.1016/0891-5849(94)00198-S ↗
31. 10.1016/j.cell.2010.01.00910.1016/j.cell.2010.01.009 ↗
32. 10.1038/nchembio.171210.1038/nchembio.1712 ↗
33. 10.1002/ange.20130492210.1002/ange.201304922 ↗
34. Ginimuge P. R. · J. Anaesthesiol Clin Pharmacol · 2010 · 26 · 51710.4103/0970-9185.74599 ↗
35. 10.1021/ja511420n10.1021/ja511420n ↗
36. 10.1021/cm403505s10.1021/cm403505s ↗
37. 10.1002/anie.20141145610.1002/anie.201411456 ↗
38. 10.1016/j.talanta.2014.09.02810.1016/j.talanta.2014.09.028 ↗
39. 10.7554/eLife.0252310.7554/eLife.02523 ↗
40. 10.1016/j.canlet.2013.12.02810.1016/j.canlet.2013.12.028 ↗
41. 10.1038/nature0416510.1038/nature04165 ↗
42. 10.1021/acsnano.8b0145610.1021/acsnano.8b01456 ↗
43. 10.1016/j.biomaterials.2014.12.02810.1016/j.biomaterials.2014.12.028 ↗
44. 10.3389/fnins.2018.0021410.3389/fnins.2018.00214 ↗
45. 10.1016/j.tips.2017.02.00510.1016/j.tips.2017.02.005 ↗
46. 10.1002/ange.20140574210.1002/ange.201405742 ↗
47. 10.1002/adma.20150586910.1002/adma.201505869 ↗
48. 10.1016/j.jbbm.2005.10.00310.1016/j.jbbm.2005.10.003 ↗
49. 10.1002/adma.20180200610.1002/adma.201802006 ↗
50. 10.1016/j.jconrel.2017.09.01410.1016/j.jconrel.2017.09.014 ↗